Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Collegium (Nasdaq: COLL) reported Q1 2026 product revenues of $193.5M (up 9% YoY) and JORNAY PM net revenue of $38.9M (up 36% YoY). Adjusted EBITDA was $103.9M, GAAP net income was $14.5M, and cash, equivalents and marketable securities totaled $421.8M. The company expects to close the $650M acquisition of AZSTARYS in Q2 2026, reaffirmed full-year 2026 guidance for the current business, and scheduled a May 7, 2026 conference call.
AI-generated analysis. Not financial advice.
Positive
- Product revenues of $193.5M in Q1 2026, +9% YoY
- JORNAY PM revenue $38.9M, +36% YoY; prescriptions >206,000 (+14% YoY)
- Adjusted EBITDA of $103.9M, +9% YoY
- Cash, cash equivalents and marketable securities of $421.8M
- Planned acquisition of AZSTARYS for $650M, expected Q2 2026 close and immediate adjusted EBITDA accretion
Negative
- GAAP operating expenses rose to $86.4M in Q1 2026, +14% YoY
- Adjusted operating expenses increased to $69.3M, +11% YoY
- Acquisition includes up to $135M in contingent milestone payments
- Full-year 2026 guidance is reaffirmed but currently excludes the impact of the planned AZSTARYS acquisition
News Market Reaction – COLL
On the day this news was published, COLL gained 7.72%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $92M to the company's valuation, bringing the market cap to $1.28B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COLL was up 3.37% pre-release while peers were mixed: PCRX -5.95%, DVAX +0.06%, AMPH +1.94%, EVO +4.52%, HROW -1.01%, pointing to stock-specific positioning rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Q4/FY 2025 earnings | Positive | -3.3% | Reported strong 2025 growth, record revenues, reaffirmed 2026 guidance and cash build. |
| Nov 06 | Q3 2025 earnings | Positive | +13.4% | Record Q3 revenue, raised 2025 revenue and adjusted EBITDA guidance. |
| Aug 07 | Q2 2025 earnings | Positive | +10.7% | Record Q2 revenue, strong Jornay PM and pain portfolio growth, higher 2025 outlook. |
| May 08 | Q1 2025 earnings | Positive | +5.9% | Strong Q1 revenue, ADHD sales force expansion, cash build and guidance reaffirmed. |
| Feb 27 | Q4/FY 2024 earnings | Positive | +2.2% | Record Q4 and full-year 2024 revenue, strong EBITDA and key product growth. |
Earnings releases have generally been received positively, with 4 of the last 5 tagged earnings events seeing share-price moves aligned with the constructive tone of the results.
Over the past several earnings cycles, Collegium has delivered consistent growth across product revenues and adjusted EBITDA while building its ADHD and pain portfolios. Recent reports highlighted record quarterly revenues, strong Jornay PM growth, and rising cash balances, alongside reaffirmed or raised guidance. The current Q1 2026 results continue this pattern, with higher product revenues, expanding JORNAY PM contribution, and solid adjusted EBITDA, following on from the strong full-year 2025 performance and previously reiterated 2026 outlook.
Historical Comparison
In the past year, Collegium’s earnings releases saw an average move of 5.79%, with most reports aligning positively with strong revenue and EBITDA trends.
Recent earnings chronicle a progression from record 2024 results to strong 2025 growth and reaffirmed 2026 guidance, with Jornay PM and the pain portfolio consistently driving higher revenues and adjusted EBITDA.
Market Pulse Summary
The stock moved +7.7% in the session following this news. A strong positive reaction aligns with Collegium’s track record of delivering solid earnings and reaffirmed guidance. Recent quarters highlighted rising product revenues and robust adjusted EBITDA, while Q1 2026 adds accelerated JORNAY PM growth and progress toward the AZSTARYS acquisition. Investors have historically rewarded similar updates, though elevated expectations and prior insider selling activity could introduce volatility if growth or integration milestones fall short of prior trends.
Key Terms
adjusted EBITDA financial
authorized generic financial
GAAP financial
non-GAAP financial
Rule 10b5-1 trading plan regulatory
AI-generated analysis. Not financial advice.
– Generated Quarterly Net Revenues of
– Generated JORNAY PM® Quarterly Net Revenue of
– On Track to Close Acquisition of AZSTARYS® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –
– Generated Quarterly Pain Portfolio Net Revenues of
– Ended Q1’26 with Cash, Cash Equivalents and Marketable Securities of
– Reaffirmed Full-Year 2026 Guidance for the Current Business –
– Conference Call Scheduled for Today at 8:00 a.m. ET –
STOUGHTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended March 31, 2026, and provided a business update.
“In the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continued durability from our pain portfolio” said Vikram Karnani, President and Chief Executive Officer. “We generated additional growth for JORNAY PM, with net revenue up
“We delivered strong first quarter results, marked by significant net revenue growth for JORNAY PM, robust contributions from our pain portfolio, and impressive operating cash flows,” said Colleen Tupper, Chief Financial Officer. “Our strong financial position enabled us to continue to execute on our capital deployment strategy, fueling the proposed acquisition of AZSTARYS. We expect the acquisition to be immediately accretive upon close and to extend our revenues into the late 2030s. Following an encouraging start to the year, we are well positioned to achieve our strategic priorities and financial commitments as we work to drive long-term shareholder value.”
ADHD Business Highlights
- Generated JORNAY PM net revenue of
$38.9 million , up36% year-over-year in the quarter ended March 31, 2026 (the 2026 Quarter). - JORNAY PM prescriptions reached an all-time high in the 2026 Quarter, with over 206,000 prescriptions written, up
14% year-over-year. - JORNAY PM prescribers reached an all-time high in the 2026 Quarter with approximately 30,000 healthcare providers writing JORNAY PM prescriptions, up
17% year-over-year. - In March, announced the acquisition of AZSTARYS from Corium Therapeutics for
$650 million in cash with the potential for additional milestone payments up to$135 million contingent on future commercial and manufacturing milestones. The acquisition will add a highly complementary and differentiated medicine with significant growth potential to Collegium’s existing ADHD portfolio. The acquisition is expected to close in the second quarter of 2026 and be immediately accretive to adjusted EBITDA. - In March, launched the ‘Embrace Your Sparkle’ campaign with Paris Hilton, aimed at encouraging broader understanding and an open dialogue about ADHD.
- In February, announced a multi-year sponsorship for a sensory room with Boston Legacy FC, a member of the National Women's Soccer League (NWSL), to help make games accessible and inclusive for more fans while raising awareness and encouraging understanding of neurodevelopmental disorders, such as ADHD.
- In January, presented four posters at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference highlighting real-world JORNAY PM data.
Pain Portfolio Highlights
- Generated pain portfolio net revenues of
$154.6 million in the 2026 Quarter, up4% year-over-year. - Generated Belbuca® net revenue of
$52.6 million in the 2026 Quarter, up2% year-over-year. - Generated Xtampza® ER net revenue of
$50.8 million in the 2026 Quarter, up7% year-over-year. - Generated Nucynta® Franchise net revenue of
$47.0 million in the 2026 Quarter, flat year-over-year. This includes$2.7 million from Hikma Pharmaceuticals USA Inc. (Hikma) for the sale of the authorized generic (AG) versions of Nucynta and Nucynta ER, both launched in the 2026 Quarter. Under the terms of the AG agreement, Collegium will receive a significant share of net profits of the AG products from Hikma. - In March, presented two posters at PainConnect 2026 showcasing real-world data from the pain portfolio.
Corporate Updates
- In April, announced proposed updates to Collegium’s Board of Directors effective as of the date of Collegium’s 2026 Annual Meeting of Shareholders on May 14, 2026 (the Annual Meeting). Michael Donovan, who most recently served as an audit Partner at Ernst & Young LLP and brings significant audit and biotechnology industry experience, is nominated to stand for election at the Annual Meeting. In addition, current Board member Dr. John Fallon will retire after having dutifully served since 2016.
Upcoming Events
The Company will participate in the following upcoming investor conferences in the second quarter of 2026:
- Jefferies Global Healthcare Conference – New York, NY; June 3, 2026.
Financial Guidance for 2026
The Company reaffirms its full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net and Adjusted EBITDA for its current business, not including the impact of the planned acquisition of AZSTARYS. Collegium expects to update 2026 guidance following the close of the acquisition.
| Product Revenues, Net | |
| JORNAY PM Revenue, Net | |
| Adjusted EBITDA | |
Financial Results for Quarter Ended March 31, 2026
- Product revenues, net were
$193.5 million for the 2026 Quarter, compared to$177.8 million for the quarter ended March 31, 2025 (the 2025 Quarter), representing a9% increase year-over-year. - GAAP operating expenses were
$86.4 million for the 2026 Quarter, compared to$75.6 million for the 2025 Quarter, representing a14% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were$69.3 million for the 2026 Quarter, compared to$62.2 million for the 2025 Quarter, representing an11% increase year-over-year. - GAAP net income for the 2026 Quarter was
$14.5 million , with$0.45 GAAP earnings per share (basic) and$0.40 GAAP earnings per share (diluted), compared to GAAP net income for the 2025 Quarter of$2.4 million , with$0.08 GAAP earnings per share (basic) and$0.07 GAAP earnings per share (diluted). Non-GAAP adjusted net income for the 2026 Quarter was$69.2 million , with$1.76 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2025 Quarter of$57.4 million , with$1.49 adjusted earnings per share. - Adjusted EBITDA for the 2026 Quarter was
$103.9 million , compared to$95.2 million for the 2025 Quarter, representing a9% increase year-over-year. - The Company generated
$57.1 million in cash from operations, and exited the 2026 Quarter with cash, cash equivalents and marketable securities of$421.8 million .
Conference Call Information
The Company will host a conference call and live audio webcast on Thursday, May 7, 2026, at 8:00 a.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical First Quarter 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by JORNAY PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with JORNAY PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management.
In this press release we discuss the following financial measures that are not calculated in accordance with GAAP.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:
- adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
- adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
- adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;
- adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
- we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
- we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
- we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business;
- we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items or, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred;
- we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition related expenses incurred;
- we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business;
- we exclude changes in the fair value of contingent consideration, which are non-cash, acquisition-related items that are not part of our underlying business;
- we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis;
- we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and
- we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis.
The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted EBITDA to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expenses, amortization of acquired intangible assets, and changes in fair value of contingent consideration. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to the expected closing of the acquisition of AZSTARYS; the anticipated benefits of the AZSTARYS acquisition, including its impact on Collegium’s ADHD portfolio and commercial strategy; projected financial performance, including expected revenue and adjusted EBITDA, statements related to current and future market opportunities for our products and our assumptions related thereto and other statements that are not historic facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: our ability to complete the AZSTARYS acquisition on the proposed terms and schedule or at all; the failure (or delay) to receive the required regulatory approvals relating to the AZSTARYS acquisition; risks related to our ability to realize the anticipated benefits of the AZSTARYS acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
| Collegium Pharmaceutical, Inc. Unaudited Selected Consolidated Balance Sheet Information (in thousands) | |||||||
| March 31, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Cash and cash equivalents | $ | 268,648 | $ | 231,252 | |||
| Marketable securities | 153,105 | 155,427 | |||||
| Accounts receivable, net | 228,762 | 211,328 | |||||
| Inventory | 42,741 | 40,912 | |||||
| Prepaid expenses and other current assets | 32,562 | 32,642 | |||||
| Property and equipment, net | 11,661 | 12,013 | |||||
| Operating lease assets | 3,975 | 4,187 | |||||
| Intangible assets, net | 614,037 | 669,510 | |||||
| Restricted cash | 20,908 | 20,906 | |||||
| Deferred tax assets | 113,567 | 112,539 | |||||
| Other noncurrent assets | 16,064 | 20,193 | |||||
| Goodwill | 145,925 | 145,925 | |||||
| Total assets | $ | 1,651,955 | $ | 1,656,834 | |||
| Accounts payable and accrued liabilities | $ | 64,976 | $ | 73,123 | |||
| Accrued rebates, returns and discounts | 317,691 | 318,266 | |||||
| Business combination consideration payable | 17,565 | 17,565 | |||||
| Term notes payable | 564,348 | 571,112 | |||||
| Convertible senior notes | 238,472 | 238,213 | |||||
| Operating lease liabilities | 5,236 | 5,539 | |||||
| Deferred royalty obligation | 121,634 | 121,563 | |||||
| Deferred revenue | 9,611 | 9,778 | |||||
| Shareholders’ equity | 312,422 | 301,675 | |||||
| Total liabilities and shareholders’ equity | $ | 1,651,955 | $ | 1,656,834 | |||
| Collegium Pharmaceutical, Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Product revenues, net | $ | 193,520 | $ | 177,757 | |||
| Cost of product revenues | |||||||
| Cost of product revenues (excluding intangible asset amortization) | 20,801 | 24,960 | |||||
| Intangible asset amortization | 55,473 | 55,473 | |||||
| Total cost of product revenues | 76,274 | 80,433 | |||||
| Gross profit | 117,246 | 97,324 | |||||
| Operating expenses | |||||||
| Selling, general and administrative | 86,350 | 76,423 | |||||
| Gain on fair value remeasurement of contingent consideration | — | (786 | ) | ||||
| Total operating expenses | 86,350 | 75,637 | |||||
| Income from operations | 30,896 | 21,687 | |||||
| Interest expense | (15,862 | ) | (20,790 | ) | |||
| Interest income | 3,706 | 2,225 | |||||
| Income before income taxes | 18,740 | 3,122 | |||||
| Provision for income taxes | 4,244 | 705 | |||||
| Net income | $ | 14,496 | $ | 2,417 | |||
| Earnings per share — basic | $ | 0.45 | $ | 0.08 | |||
| Weighted-average shares — basic | 32,087,472 | 31,793,739 | |||||
| Earnings per share — diluted | $ | 0.40 | $ | 0.07 | |||
| Weighted-average shares — diluted | 40,065,665 | 32,840,153 | |||||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| GAAP net income | $ | 14,496 | $ | 2,417 | |||
| Adjustments: | |||||||
| Interest expense | 15,862 | 20,790 | |||||
| Interest income | (3,706 | ) | (2,225 | ) | |||
| Provision for income taxes | 4,244 | 705 | |||||
| Depreciation | 463 | 1,091 | |||||
| Amortization | 55,473 | 55,473 | |||||
| Stock-based compensation | 10,880 | 11,524 | |||||
| Recognition of step-up basis in inventory | — | 3,477 | |||||
| Executive transition expense | — | 1,397 | |||||
| Acquisition related expenses | 6,175 | 1,289 | |||||
| Gain on fair value remeasurement of contingent consideration | — | (786 | ) | ||||
| Total adjustments | $ | 89,391 | $ | 92,735 | |||
| Adjusted EBITDA | $ | 103,887 | $ | 95,152 | |||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| GAAP operating expenses | $ | 86,350 | $ | 75,637 | |||
| Adjustments: | |||||||
| Stock-based compensation | 10,880 | 11,524 | |||||
| Executive transition expense | — | 1,397 | |||||
| Acquisition related expenses | 6,175 | 1,289 | |||||
| Gain on fair value remeasurement of contingent consideration | — | (786 | ) | ||||
| Total adjustments | $ | 17,055 | $ | 13,424 | |||
| Adjusted operating expenses | $ | 69,295 | $ | 62,213 | |||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts) (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| GAAP net income | $ | 14,496 | $ | 2,417 | |||
| Adjustments: | |||||||
| Non-cash interest expense | 819 | 1,367 | |||||
| Amortization | 55,473 | 55,473 | |||||
| Stock-based compensation | 10,880 | 11,524 | |||||
| Recognition of step-up basis in inventory | — | 3,477 | |||||
| Executive transition expense | — | 1,397 | |||||
| Acquisition related expenses | 6,175 | 1,289 | |||||
| Gain on fair value remeasurement of contingent consideration | — | (786 | ) | ||||
| Income tax effect of above adjustments (1) | (18,629 | ) | (18,737 | ) | |||
| Total adjustments | $ | 54,718 | $ | 55,004 | |||
| Non-GAAP adjusted net income | $ | 69,214 | $ | 57,421 | |||
| Adjusted weighted-average shares — diluted (2) | 40,065,665 | 39,446,458 | |||||
| Adjusted earnings per share (2) | $ | 1.76 | $ | 1.49 | |||
| (1) | The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended March 31, 2026 and 2025 were |
| (2) | Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three months ended March 31, 2026 and 2025, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive. |
